Last year’s solid venture capital investment in life sciences was, as expected, focused on the big three markets of San Diego, Boston, and San Francisco. But as a recent Cushman & Wakefield report found, emerging markets saw significant spikes of interest, perhaps suggesting a shift toward building startups and more lab space outside established markets....By: Allen Matkins.